Palivizumab.
Gupta
D
D
Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi 110 095, India.
Gupta
P
P
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000628:therapy*; D012136:Respiratory Syncytial Viruses / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab